MYR was founded in 2010 and is based in Burgwedel, Germany, supported by investors Maxwell Biotech and High-Tech Gründerfonds (HTGF).
Hepatera, on the other hand, is actually the first Russian biotech we’ve encountered – which is perhaps an early indication of the emerging market growing in Moscow.
For example, investors of Hepatera also include Maxwell Biotech Venture Fund (MBVF). This is the first Russian venture fund fully dedicated to investments in the life sciences sector, created with the participation of the Russian Government‘s Russian Venture Company (RVC).
Hepatera’s focus is the development of safe and effective drugs for the treatment of liver diseases for the Russian market, and this includes Myrcludex B in partnership with MYR.